-
Greenlane To Raise $6.5M Through Private Investment Deal With Large Institutional Investor
Tuesday, August 13, 2024 - 1:05pm | 425Read More...Greenlane Holdings (NASDAQ:GNLN) announced Monday that it has entered into a securities purchase agreement with a large institutional investor for aggregate gross cash proceeds of $6.5 million. Under the agreement, the vendor of cannabis accessories and vaporization products will issue 3.36 million...
-
Market Dumps Match Group Despite Q3 Beat
Wednesday, November 7, 2018 - 5:26pm | 485Read More...Shares of Tinder parent company Match Group Inc (NASDAQ: MTCH) fell 17 percent Wednesday after the company released its third-quarter print the previous afternoon. The online dating company reported Q3 adjusted earnings of 39 cents per share, beating estimates by 3 cents. Sales came in...
-
Recent Selloff In Nautilus Shares Has Created A Buying Opportunity
Monday, September 11, 2017 - 8:59am | 387Read More...Shares of Nautilus, Inc. (NYSE: NLS) have fallen 10 percent over the past three months, and the decline has created a buying opportunity, according to analysts at Aegis Capital Corp. The firm's Rommel Dionisio initiated coverage of Nautilus' stock with a Buy rating and $21 price target. Nautilus...
-
Why Aegis Capital Loves Adamas...And How To Bet On Parkinson's Treatment
Tuesday, September 22, 2015 - 11:17am | 300Read More...The share price of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) has risen a little over 13 percent year-to-date. Aegis Capital’s Robert LeBoyer has initiated coverage of Adamas Pharmaceuticals with a price target of $29. LeBoyer expects the stock to be driven by the Phase III data...
-
IPO Outlook: Fitbit Running On Pace For This Week's Hot IPO
Monday, June 15, 2015 - 1:05pm | 1515Read More...The wearable fitness tracker company Fitbit, Inc. hopes to raise $358 million this Friday in what could be the hottest IPO of 2015. With great growth across the board, the company plans to issue 22.4 million shares between $14 and $16 per share on the NYSE under the ticker FIT. What Is Fitbit?...
-
Aegis Capital Rates Alcobra as a Top Pick in 2014
Thursday, January 2, 2014 - 3:03pm | 268Read More...In a report published Thursday, Aegis Capital Corp analyst Raghuram Selvaraju rates Alcobra (NASDAQ: ADHD) as a top pick in 2014. Selvaraju noted the “compelling value proposition” in Alcobra shares. The analyst commented on value drivers in 2014 including the enrollment in the first or two Phase...
-
UPDATE: Aegis Capital Corp Initiates Buy on Acorda Therapeutics on Ampyra Visibility
Tuesday, August 21, 2012 - 1:07pm | 145Read More...Aegis Capital Corp initiated its rating on Acorda Therapeutics (NASDAQ: ACOR) with a Buy rating and a price target of $32 a share. Aegis Capital Corp commented, "We Believe Ampyra is an Undervalued Growth Asset. The patient population that Ampyra™ targets in the MS market is the largest of any...
